Provided by Tiger Trade Technology Pte. Ltd.

Dare Bioscience

0.7506
-0.0701-8.54%
Post-market: 0.75290.0023+0.31%18:23 EDT
Volume:952.68K
Turnover:735.71K
Market Cap:14.54M
PE:-0.96
High:0.8472
Open:0.8332
Low:0.7400
Close:0.8207
52wk High:3.78
52wk Low:0.7400
Shares:19.38M
Float Shares:18.13M
Volume Ratio:1.82
T/O Rate:5.26%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.7779
EPS(LYR):-1.1986
ROE:-2543.13%
ROA:-39.29%
PB:-25.93
PE(LYR):-0.63

Loading ...

Daré Bioscience Reports Second Quarter 2026 Results and Highlights Commercial Inflection as Multi-Product Women’s Health Strategy Advances

GlobeNewswire
·
Aug 14

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Aug 13

Dare Bioscience Inc Expected to Post a Loss of 24 Cents a Share - Earnings Preview

Reuters
·
Aug 12

Daré Bioscience to Host Quarterly Results Conference Call and Webcast

Reuters
·
Aug 06

DarÉ Bioscience Expands Access Options for Dare to Play™ and Specialized Menopause Care Through Strategic Collaboration with Mymenopauserx

THOMSON REUTERS
·
Jul 28

Daré Bioscience Expands Access Options for DARE to PLAY™ and Specialized Menopause Care Through Strategic Collaboration with MyMenopauseRx

GlobeNewswire
·
Jul 28

Daré Bioscience, Inc. (NASDAQ:DARE): Are Analysts Optimistic?

Simply Wall St.
·
Jul 21

Daré Bioscience Launches Nationwide Virtual Bus Tour Webinar Series to Showcase Commercial Strategy and Growth Opportunities

GlobeNewswire
·
Jul 20

Daré Bioscience Advances DARE-HPV Trial, Raising New Questions for HPV Treatment Investors

TIPRANKS
·
Jul 18

Daré Bioscience CEO, Sabrina Martucci Johnson, to Participate in Virtual Investor Closing Bell Event

GlobeNewswire
·
Jul 09

Daré Bioscience Announces Flora Sync LF5™ Is Now Available Through Its Direct-to-Consumer Platform

GlobeNewswire
·
Jul 01

Daré Bioscience Highlights Revenue Opportunity as CEO Discusses Upcoming Launch of Flora Sync LF5™ in Virtual Investor “What This Means” Segment

GlobeNewswire
·
Jun 25

Daré Bioscience CEO speaks at BIO International Convention 2026

Reuters
·
Jun 18

Daré Bioscience shareholders approve 1.5 million-share increase to 2022 stock incentive plan at annual meeting

Reuters
·
Jun 13

DarÉ Bioscience Announces the Upcoming Launch of Flora Sync Lf5™ Vaginal Probiotic Capsules

THOMSON REUTERS
·
Jun 04

Daré Bioscience wins $1 million NIH grant tranche for DARE-HPV program

Reuters
·
May 26

Press Release: Daré Bioscience Receives NIH Funding Award Notice to Advance DARE-HPV, its Novel Investigational Treatment for Persistent High-Risk HPV Infection, the Most Common Cause of Cervical Cancer

Dow Jones
·
May 26

BRIEF-Daré Bioscience Initiates Phase 2 Study Of Dare-Hpv

Reuters
·
May 18

Daré Bioscience starts Phase 2 trial of DARE-HPV vaginal insert for high-risk HPV infection

Reuters
·
May 18

DarÉ Bioscience Initiates Phase 2 Study of Dare-Hpv, a Novel Pharmacologic Treatment for Persistent High-Risk Hpv Infection With No FDA-Approved Therapies

THOMSON REUTERS
·
May 18